This is a Cost No Fee definitive contract awarded by the Food and Drug Administration (FDA) to the University of California, Los Angeles (UCLA) to develop a biobank that can be used to characterize the durability and correlates of vaccine-induced and natural immunity to Ebola virus disease (EVD). The $7,332,682.00 contract has an ultimate completion date of March 22, 2025. UCLA will leverage its facilities, faculty expertise, and administrative capabilities to support this FDA initiative. The contract does not have a set-aside designation. UCLA's parent organization is the State of California Controller's Office, which has also received multiple federal contract and grant awards for technology support, consulting services, and research programs. This contract supports the FDA's high-level objectives in the areas of public health and medical countermeasures for emerging infectious diseases.